C. Randal Mills

Dr. Randy Mills, Ph.D., co-founder of Aziyo Biologics, has served as a member of Aziyo’s board of directors since November 2015. Randy and Kevin Rakin started Aziyo with the vision to build a regenerative medicine company to improve the lives of patients by developing a pipeline of cutting-edge biosurgical products.

Dr. Mills is an internationally recognized expert in regenerative medicine who has led pioneering biotechnology organizations that have created more than $1 billion in shareholder value for investors. As CEO of Osiris Therapeutics (Nasdaq: OSIR), he commercialized five cell-therapy products responsible for $1.5 billion in sales and led the company through an IPO that increased shareholder value 41-fold. Osiris was eventually sold to Smith and Nephew for $660 million. Dr. Mills was also a co-founder and officer of Regeneration Technologies (Nasdaq: RTIX), where he led operations, R&D, regulatory, and business development through its successful IPO.